• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

作者信息

Krenning E P, Kooij P P, Bakker W H, Breeman W A, Postema P T, Kwekkeboom D J, Oei H Y, de Jong M, Visser T J, Reijs A E

机构信息

Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands.

出版信息

Ann N Y Acad Sci. 1994 Sep 15;733:496-506. doi: 10.1111/j.1749-6632.1994.tb17300.x.

DOI:10.1111/j.1749-6632.1994.tb17300.x
PMID:7978900
Abstract
摘要

相似文献

1
Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.
Ann N Y Acad Sci. 1994 Sep 15;733:496-506. doi: 10.1111/j.1749-6632.1994.tb17300.x.
2
Current imaging and possible therapeutic management of glucagonoma tumors: a case report.胰高血糖素瘤的当前影像学检查及可能的治疗处理：一例病例报告
Clin Nucl Med. 2000 Feb;25(2):120-2. doi: 10.1097/00003072-200002000-00008.
3
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.一种新的放射性标记生长抑素类似物[111铟-二乙三胺五乙酸-D-苯丙氨酸1]RC-160：制备、生物活性、大鼠体内受体闪烁显像及与[111铟-二乙三胺五乙酸-D-苯丙氨酸1]奥曲肽的比较
Eur J Nucl Med. 1994 Apr;21(4):328-35.
4
Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.将铟-111与铟-111-二乙三胺五乙酸-D-苯丙氨酸-1-奥曲肽一起孵育后，铟-111在人神经内分泌肿瘤细胞中的内化。
J Nucl Med. 1996 Dec;37(12):2002-6.
5
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.肿瘤的生长抑素受体靶向放射性核素治疗：临床前及临床研究结果
Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027.
6
[A case of metastatic gastrinomas in the liver visualized by 111In-DTPA-D-Phe-octreotide (111In-pentetreotide)].111铟-二乙三胺五乙酸- D -苯丙氨酸-奥曲肽（111铟-喷替肽）显像诊断肝转移胃泌素瘤1例
Kaku Igaku. 1996 May;33(5):545-9.
7
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.使用标记生长抑素类似物的治疗：111铟-二乙三胺五乙酸-D-苯丙氨酸1-奥曲肽与钇标记的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-奥曲肽吸收剂量的比较。
Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e.
8
Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.使用铟 - 111 - DTPA - D - 苯丙氨酸 - 1 - 奥曲肽进行中肠类癌综合征的全身放射性核素治疗。
J Nucl Med. 1996 Sep;37(9):1519-21.
9
In vitro and in vivo evaluation of copper-64-octreotide conjugates.铜-64-奥曲肽偶联物的体外和体内评估。
J Nucl Med. 1995 Dec;36(12):2315-25.
10
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.[111铟-二乙三胺五乙酸-D-苯丙氨酸1]-奥曲肽，一种用于生长抑素受体阳性肿瘤成像的潜在放射性药物：合成、放射性标记及体外验证
Life Sci. 1991;49(22):1583-91. doi: 10.1016/0024-3205(91)90052-d.

引用本文的文献

1
Aggressiveness in Well-Differentiated Small Intestinal Neuroendocrine Tumors: A Rare Case and Narrative Literature Review.高分化小肠神经内分泌肿瘤的侵袭性：1例罕见病例及文献综述
J Clin Med. 2025 Aug 18;14(16):5821. doi: 10.3390/jcm14165821.
2
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.放射性核素标记的生物材料：肿瘤靶向治疗的新策略。
Biomimetics (Basel). 2025 Jun 11;10(6):394. doi: 10.3390/biomimetics10060394.
3
Prognosis of NETs: Has There Been Improvement over the Last 30 Years?神经内分泌肿瘤的预后：在过去30年里有改善吗？
Neuroendocrinology. 2025 May 30:1-13. doi: 10.1159/000546613.
4
NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry.NOTA和NODAGA放射性核素络合剂：放射化学进展的通用方法。
Molecules. 2025 May 8;30(10):2095. doi: 10.3390/molecules30102095.
5
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.使用生长抑素类似物进行肽受体放射性核素治疗，治疗范围超出胃肠胰神经内分泌肿瘤。
J Neuroendocrinol. 2025 Mar;37(3):e70013. doi: 10.1111/jne.70013. Epub 2025 Mar 10.
6
Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres.加拿大两个癌症中心胰腺神经内分泌肿瘤（pNET）患者的治疗模式
Curr Oncol. 2025 Feb 3;32(2):86. doi: 10.3390/curroncol32020086.
7
The Value of Repeat 5-HIAA Measurements as a Predictor of Carcinoid Heart Disease: A Prospective 5-Year Follow-Up Study in Patients with Small Intestinal Neuroendocrine Tumors.重复5-羟吲哚乙酸测量作为类癌性心脏病预测指标的价值：一项针对小肠神经内分泌肿瘤患者的前瞻性5年随访研究。
Cancers (Basel). 2024 Nov 21;16(23):3896. doi: 10.3390/cancers16233896.
8
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.肽受体放射性核素治疗转移性神经内分泌肿瘤引起的异位库欣综合征。
Endocr Oncol. 2024 Nov 20;4(1):e240013. doi: 10.1530/EO-24-0013. eCollection 2024 Jan 1.
9
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.1级和2级胃肠胰神经内分泌肿瘤的肽受体放射性核素治疗现状
J Neuroendocrinol. 2025 Mar;37(3):e13469. doi: 10.1111/jne.13469. Epub 2024 Nov 20.
10
Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.肽受体放射性核素治疗可改善胃肠胰神经内分泌肿瘤切除术后进展患者的生存率。
Ann Surg Oncol. 2025 Feb;32(2):1136-1148. doi: 10.1245/s10434-024-16463-7. Epub 2024 Nov 6.